Luengo, Alba http://orcid.org/0000-0002-4236-0229
Abbott, Keene L. http://orcid.org/0000-0002-6166-704X
Davidson, Shawn M.
Hosios, Aaron M.
Faubert, Brandon http://orcid.org/0000-0002-2886-886X
Chan, Sze Ham
Freinkman, Elizaveta
Zacharias, Lauren G.
Mathews, Thomas P.
Clish, Clary B. http://orcid.org/0000-0001-8259-9245
DeBerardinis, Ralph J.
Lewis, Caroline A. http://orcid.org/0000-0003-1787-5084
Vander Heiden, Matthew G. http://orcid.org/0000-0002-6702-4192
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA168653)
Article History
Received: 28 August 2019
Accepted: 5 November 2019
First Online: 6 December 2019
Competing interests
: M.G.V.H. and R.J.D. disclose that they are scientific advisory members for Agios Pharmaceuticals and M.G.V.H is a scientific advisory board member for Aeglea Biotherapeutics, Auron Therapeutics, and iTeos Therapeutics. Since the completion of this work A.L. has started a position at a Flagship Pioneering biotechnology start-up company. All other authors declare no competing interests.